Pluristem Therapeutics stated that a pilot study of its PLX-R18 cell therapy will be initiated by the US Department of Defense’s (DOD) Armed Forces Radiobiology Research Institute (AFRRI), part of the Uniformed Services University of Health Sciences (USU).
The National Institute of Allergy and Infectious Diseases (NIAID) and National Institutes of Health (NIH) have awarded a Small Business Initiative Research (SBIR) grant to Aradigm to study the treatment of two pulmonary non-tuberculous mycobacteria (PNTM) infections, Mycobacterium avium and Mycobacterium abscessus, with the company’s inhaled liposomal ciprofloxacin products Linhaliq and Lipoquin.
Ophthotech’s anti-PDGF therapy Fovista (pegpleranib) for treating wet age-related macular degeneration (AMD) has failed to meet the primary endpoint in a phase 3 trial.
Heron Therapeutics has reported positive outcome of a recent End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) regarding its investigational agent, HTX-011, to prevent postoperative pain for the first 72 hours post surgery.
Amylyx Pharmaceuticals, in collaboration with The ALS Association, ALS Finding a Cure, and the Massachusetts General Hospital, has dosed the first patient in the CENTAUR study, a Phase II clinical trial assessing the efficacy and safety of AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS).
Zynerba Pharmaceuticals has reported that its cannabis-based epilepsy gel ZYN002 (cannabidiol [CBD] gel) has failed to meet the primary point in a phase 2 clinical trial.
Eli Lilly's migraine drug Lasmiditan has met its primary endpoint in a second phase 3 trial.
Orbsen Therapeutics’ stromal cell immunotherapy, OBRCEL-M has been approved to begin testing in a randomised, double blind, and placebo-controlled clinical trial in Europe to treat diabetic kidney disease.
Generex Biotechnology's subsidiary, Antigen Express has signed a clinical trial collaboration agreement with Merck, via a wholly-owned subsidiary, to assess Antigen’s AE37 cancer vaccine in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA (pembrolizumab), in patients with metastatic triple-negative breast cancer.
AstraZeneca’s Imfinzi (durvalumab) in combination with tremelimumab failed to improve progression-free survival (PFS) significantly in a phase 3 trial in previously untreated patients having advanced lung cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.